PCVX
$55.48
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococca...
Recent News
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)?
Vaxcyte, Inc. reported a full-year 2025 net loss of US$766.63 million, with basic loss per share from continuing operations of US$5.63, and simultaneously moved to strengthen its balance sheet through a US$408.10 million follow-on equity raise and an additional US$500 million at-the-market program. Alongside these financing steps, Vaxcyte filed a US$473.86 million shelf registration tied to employee stock plans and advanced its VAX-31 pneumococcal vaccine program into multiple late-stage...
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.
For growth-focused biotech investors, Vaxcyte is no longer just a science story.
Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists
Vaxcyte (NasdaqGS:PCVX) reported unprecedented Phase 2 results in adults for its 31-valent pneumococcal vaccine candidate, VAX-31. The company is moving rapidly into multiple Phase 3 trials following the positive Phase 2 data. A large-scale manufacturing facility has been completed to support potential future commercial supply. Vaxcyte has appointed a new Chief Commercial Officer as it prepares for possible global commercialization. For investors watching Vaxcyte at a share price of $61.74,...
A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds
Vaxcyte (PCVX) has been drawing attention after recent share price moves, with the stock closing at US$61.74 and showing mixed total returns over the past year and multi year periods. See our latest analysis for Vaxcyte. The recent 1 month share price return of 15.25% and 90 day return of 35.63% suggest momentum has been building, even though the 1 year total shareholder return of a 15.45% decline contrasts with the much stronger 3 and 5 year total shareholder returns of 45.13% and...
Vaxcyte, Inc. Q4 2025 Earnings Call Summary
Moby summary of Vaxcyte, Inc.'s Q4 2025 earnings call